Federica Pecci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Federica Pecci has a total of 248 co-authors. Here are the top co-authors by number of shared publications:
- Biagio Ricciuti
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
487 shared publications - Mark Magdi Awad
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
487 shared publications - Alessandro Di Federico
University of Bologna 1 Department of Medical and Surgical Sciences Bologna, Italy
486 shared publications - Joao Victor Alessi
Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
473 shared publications - Giuseppe Lamberti
Alma Mater Studiorum - University of Bologna
464 shared publications - Xinan Wang
Harvard School of Public Health, Boston, MA
421 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco
Purpose:Predictive biomarkers of response to immune checkpoint inhibitors (ICI) remain poorly defined in patients with non–small cell lung cancer (NSCLC) without a history of tobacco use and lacking actionable genomic alterations (AGA). We aimed to identify clinical and molecular predictors of response to ICI-based regimens in patients who have never smoked and lack AGAs. Experimental Design:We retrospectively analyzed patients with metastatic, AGA-negative NSCLC who never smoke treated with ICI-based regimens across multiple independent cohorts. Tumor-infiltrating lymphocyte (TIL) densities were quantified using a machine learning–based algorithm, and immune cell biomarkers were assessed with multiplexed immunofluorescence. Transcriptomic correlates of ICI response were analyzed in the Stand Up To Cancer cohort. Results:Among 741 patients with AGA-negative NSCLC and no history of tobacco use, the objective response rate (ORR) was 23.2%, median progression-free survival (mPFS) was 4.5 months, and median overall survival (mOS) was 16.8 months. PD-L1 ≥90% and tumor mutational burden (TMB) ≥90th percentile were independently and significantly associated with improved ORR, mPFS, and mOS (all P <0.01). PD-(L)1 + CTLA-4 combinations outperformed chemoimmunotherapy and PD-(L)1 monotherapy in terms of mPFS and mOS. Transcriptomic analysis revealed enrichment of innate and adaptive immune pathways in responders, including increased MHC class I/II antigen presentation and T-cell activity. High TIL density was also associated with superior ORR and PFS. Multiplexed immunophenotyping confirmed higher immune cell infiltration in patients who experienced durable clinical benefit. Conclusions:We demonstrated how combination therapies may improve ICI outcomes in patients with AGA-negative NSCLC and no history of tobacco exposure. Very high PD-L1, TMB, and immune-enriched phenotypes may guide treatment personalization.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco
Purpose:Predictive biomarkers of response to immune checkpoint inhibitors (ICI) remain poorly defined in patients with non–small cell lung cancer (NSCLC) without a history of tobacco use and lacking actionable genomic alterations (AGA). We aimed to identify clinical and molecular predictors of response to ICI-based regimens in patients who have never smoked and lack AGAs. Experimental Design:We retrospectively analyzed patients with metastatic, AGA-negative NSCLC who never smoke treated with ICI-based regimens across multiple independent cohorts. Tumor-infiltrating lymphocyte (TIL) densities were quantified using a machine learning–based algorithm, and immune cell biomarkers were assessed with multiplexed immunofluorescence. Transcriptomic correlates of ICI response were analyzed in the Stand Up To Cancer cohort. Results:Among 741 patients with AGA-negative NSCLC and no history of tobacco use, the objective response rate (ORR) was 23.2%, median progression-free survival (mPFS) was 4.5 months, and median overall survival (mOS) was 16.8 months. PD-L1 ≥90% and tumor mutational burden (TMB) ≥90th percentile were independently and significantly associated with improved ORR, mPFS, and mOS (all P <0.01). PD-(L)1 + CTLA-4 combinations outperformed chemoimmunotherapy and PD-(L)1 monotherapy in terms of mPFS and mOS. Transcriptomic analysis revealed enrichment of innate and adaptive immune pathways in responders, including increased MHC class I/II antigen presentation and T-cell activity. High TIL density was also associated with superior ORR and PFS. Multiplexed immunophenotyping confirmed higher immune cell infiltration in patients who experienced durable clinical benefit. Conclusions:We demonstrated how combination therapies may improve ICI outcomes in patients with AGA-negative NSCLC and no history of tobacco exposure. Very high PD-L1, TMB, and immune-enriched phenotypes may guide treatment personalization.
- 14 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4095-4104
Clinical Significance of EGFR Amplification in Patients with EGFR -Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib
Purpose: With rapidly expanding treatment options for patients with epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC), identifying biomarkers that may assist in treatment selection is critical. The impact of EGFR amplification (EGFRAMP) on outcomes to osimertinib is currently unknown. Experimental Design: Patients with metastatic EGFR-mutated NSCLC who received first-line osimertinib and had undergone baseline next-generation sequencing (NGS) that included assessment of EGFRAMP were included. EGFRAMP was defined as an EGFR copy number (CN) ≥6. Results: Among 473 patients, 81 (17.1%) had EGFRAMP. Compared with patients with non-amplified EGFR (EGFRNon-AMP; n = 392), they frequently had TP53 comutations (80% vs. 55.4%, P < 0.001) and brain (50.6% vs. 34.3%, P = 0.008), liver (25.9% vs. 13.5%, P = 0.009), and bone (65.4% vs. 51.3%, P = 0.028) metastases. When treated with osimertinib, patients with EGFRAMP achieved a similar objective response rate (88% vs. 83%, P = 0.23) but shorter median progression-free survival [PFS; 11.6 vs. 19 months, hazard ratio (HR), 1.77; P < 0.0001] and overall survival (OS; 34 vs. 40.1 months; HR, 1.40; P = 0.040). EGFRAMP was consistently associated with worse PFS regardless of TP53 comutations; however, EGFRAMP was associated with worse PFS and OS in patients with EGFR exon 19 deletion, but not in those with EGFR L858R. Within EGFRAMP cases, a higher EGFR CN and the amplification of the mutant allele, as opposed to wild-type amplification, correlated with inferior outcomes. Among patients reassessed with NGS after osimertinib resistance (n = 113), those with baseline EGFRAMP more frequently showed acquired MET alterations (29% vs. 12%, P = 0.04). Conclusions: EGFR AMP correlates with distinct characteristics and worse outcomes to osimertinib monotherapy among patients with EGFR-mutated NSCLC.
- 14 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4095-4104
Clinical Significance of EGFR Amplification in Patients with EGFR -Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib
Purpose: With rapidly expanding treatment options for patients with epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC), identifying biomarkers that may assist in treatment selection is critical. The impact of EGFR amplification (EGFRAMP) on outcomes to osimertinib is currently unknown. Experimental Design: Patients with metastatic EGFR-mutated NSCLC who received first-line osimertinib and had undergone baseline next-generation sequencing (NGS) that included assessment of EGFRAMP were included. EGFRAMP was defined as an EGFR copy number (CN) ≥6. Results: Among 473 patients, 81 (17.1%) had EGFRAMP. Compared with patients with non-amplified EGFR (EGFRNon-AMP; n = 392), they frequently had TP53 comutations (80% vs. 55.4%, P < 0.001) and brain (50.6% vs. 34.3%, P = 0.008), liver (25.9% vs. 13.5%, P = 0.009), and bone (65.4% vs. 51.3%, P = 0.028) metastases. When treated with osimertinib, patients with EGFRAMP achieved a similar objective response rate (88% vs. 83%, P = 0.23) but shorter median progression-free survival [PFS; 11.6 vs. 19 months, hazard ratio (HR), 1.77; P < 0.0001] and overall survival (OS; 34 vs. 40.1 months; HR, 1.40; P = 0.040). EGFRAMP was consistently associated with worse PFS regardless of TP53 comutations; however, EGFRAMP was associated with worse PFS and OS in patients with EGFR exon 19 deletion, but not in those with EGFR L858R. Within EGFRAMP cases, a higher EGFR CN and the amplification of the mutant allele, as opposed to wild-type amplification, correlated with inferior outcomes. Among patients reassessed with NGS after osimertinib resistance (n = 113), those with baseline EGFRAMP more frequently showed acquired MET alterations (29% vs. 12%, P = 0.04). Conclusions: EGFR AMP correlates with distinct characteristics and worse outcomes to osimertinib monotherapy among patients with EGFR-mutated NSCLC.
- 23 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF11
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco
Purpose: Predictive biomarkers of response to immune checkpoint inhibitors (ICI) remain poorly defined in patients with non–small cell lung cancer (NSCLC) without a history of tobacco use and lacking actionable genomic alterations (AGA). We aimed to identify clinical and molecular predictors of response to ICI-based regimens in patients who have never smoked and lack AGAs. Experimental Design: We retrospectively analyzed patients with metastatic, AGA-negative NSCLC who never smoke treated with ICI-based regimens across multiple independent cohorts. Tumor-infiltrating lymphocyte (TIL) densities were quantified using a machine learning–based algorithm, and immune cell biomarkers were assessed with multiplexed immunofluorescence. Transcriptomic correlates of ICI response were analyzed in the Stand Up To Cancer cohort. Results: Among 741 patients with AGA-negative NSCLC and no history of tobacco use, the objective response rate (ORR) was 23.2%, median progression-free survival (mPFS) was 4.5 months, and median overall survival (mOS) was 16.8 months. PD-L1 ≥90% and tumor mutational burden (TMB) ≥90th percentile were independently and significantly associated with improved ORR, mPFS, and mOS (all P <0.01). PD-(L)1 + CTLA-4 combinations outperformed chemoimmunotherapy and PD-(L)1 monotherapy in terms of mPFS and mOS. Transcriptomic analysis revealed enrichment of innate and adaptive immune pathways in responders, including increased MHC class I/II antigen presentation and T-cell activity. High TIL density was also associated with superior ORR and PFS. Multiplexed immunophenotyping confirmed higher immune cell infiltration in patients who experienced durable clinical benefit. Conclusions: We demonstrated how combination therapies may improve ICI outcomes in patients with AGA-negative NSCLC and no history of tobacco exposure. Very high PD-L1, TMB, and immune-enriched phenotypes may guide treatment personalization.
- 23 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF11
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco
Purpose: Predictive biomarkers of response to immune checkpoint inhibitors (ICI) remain poorly defined in patients with non–small cell lung cancer (NSCLC) without a history of tobacco use and lacking actionable genomic alterations (AGA). We aimed to identify clinical and molecular predictors of response to ICI-based regimens in patients who have never smoked and lack AGAs. Experimental Design: We retrospectively analyzed patients with metastatic, AGA-negative NSCLC who never smoke treated with ICI-based regimens across multiple independent cohorts. Tumor-infiltrating lymphocyte (TIL) densities were quantified using a machine learning–based algorithm, and immune cell biomarkers were assessed with multiplexed immunofluorescence. Transcriptomic correlates of ICI response were analyzed in the Stand Up To Cancer cohort. Results: Among 741 patients with AGA-negative NSCLC and no history of tobacco use, the objective response rate (ORR) was 23.2%, median progression-free survival (mPFS) was 4.5 months, and median overall survival (mOS) was 16.8 months. PD-L1 ≥90% and tumor mutational burden (TMB) ≥90th percentile were independently and significantly associated with improved ORR, mPFS, and mOS (all P <0.01). PD-(L)1 + CTLA-4 combinations outperformed chemoimmunotherapy and PD-(L)1 monotherapy in terms of mPFS and mOS. Transcriptomic analysis revealed enrichment of innate and adaptive immune pathways in responders, including increased MHC class I/II antigen presentation and T-cell activity. High TIL density was also associated with superior ORR and PFS. Multiplexed immunophenotyping confirmed higher immune cell infiltration in patients who experienced durable clinical benefit. Conclusions: We demonstrated how combination therapies may improve ICI outcomes in patients with AGA-negative NSCLC and no history of tobacco exposure. Very high PD-L1, TMB, and immune-enriched phenotypes may guide treatment personalization.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Overview of MET TKD mutations detected in pan-cancer cohorts. (A) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in the cohort #1 (711 MET TKD mutations among 664 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (B) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #1. (C) Distribution of MET TKD mutations across MET kinase domain for cohort #1. (D) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in cohort #2 (2,559 MET TKD mutations among 2,477 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (E) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #2. (F) Distribution of MET TKD mutation across MET kinase domain for cohort #2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Overview of MET TKD mutations detected in pan-cancer cohorts. (A) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in the cohort #1 (711 MET TKD mutations among 664 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (B) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #1. (C) Distribution of MET TKD mutations across MET kinase domain for cohort #1. (D) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in cohort #2 (2,559 MET TKD mutations among 2,477 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (E) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #2. (F) Distribution of MET TKD mutation across MET kinase domain for cohort #2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Frequency of MET tyrosine kinase domain (TKD) mutations in cohort #2 according to amino acid residue, out of a total of 2,559 MET TKD mutations.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Frequency of MET tyrosine kinase domain (TKD) mutations in cohort #2 according to amino acid residue, out of a total of 2,559 MET TKD mutations.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Sensitivity pattern of MET TKD mutations in 293T cells. (A) ERK-mediated transcriptional activation assessed by luciferase assay in 293T cells co-transfected with MET WT or TKD mutant constructs, an ERK activation reporter vector (pGL4.33), and a control co-reporter vector (pRL-TK). The lower panel shows western blot analysis of transfected samples. (B) Western blot analysis of MET and ERK1/2 phosphorylation in response to 1 μM crizotinib. MET TKD mutants showing sensitivity and resistance to crizotinib are colored in green and orange, respectively.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Sensitivity pattern of MET TKD mutations in 293T cells. (A) ERK-mediated transcriptional activation assessed by luciferase assay in 293T cells co-transfected with MET WT or TKD mutant constructs, an ERK activation reporter vector (pGL4.33), and a control co-reporter vector (pRL-TK). The lower panel shows western blot analysis of transfected samples. (B) Western blot analysis of MET and ERK1/2 phosphorylation in response to 1 μM crizotinib. MET TKD mutants showing sensitivity and resistance to crizotinib are colored in green and orange, respectively.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 13 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Concurrent driver mutations according to oncogenic / likely oncogenic MET TKD mutations detected in cohort #2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 13 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Concurrent driver mutations according to oncogenic / likely oncogenic MET TKD mutations detected in cohort #2.